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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.027Normal and diseased cells release bilayered membrane-bound nanovesicles into interstitial spaces and
into bodily ﬂuids. A subgroup of such microvesicles is called exosomes and is described in blood as 30
to 100 nm in diameter and as spherical to cup-shaped nanoparticles with speciﬁc surface molecular
characteristics (eg, expression of the tetraspanins CD9, CD81, and CD63). Extracellular microvesicles
provide local signals (eg, autocrine and paracrine) and distant endocrine signals to cells via the transfer
of their contents, which include signal proteins, lipids, miRNAs, and functional mRNAs. Exosomes and
related microvesicles also aid cells in exporting less-needed molecules and potentially harmful mole-
cules, including drugs; in the case of neoplasia, the export of chemotherapeutic drugs may facilitate
cellular chemoresistance. Cancers have adapted the exosome and related microvesicles as a pathway by
which neoplastic cells communicate with each other (autocrine) and with nonneoplastic cells (paracrine
and endocrine); via this pathway, cancer suppresses the immune system and establishes a fertile local
and distant environment to support neoplastic growth, invasion, and metastases. Because exosomes
mirror and bind to the cells from which they arise, they can be used for delivery of drugs, vaccines, and
gene therapy, as biomarkers and targets. We review how exosomes and related extracellular micro-
vesicles facilitate the progression and metastases of cancers and describe how these microvesicles may
affect clinical care. (Am J Pathol 2014, 184: 28e41; http://dx.doi.org/10.1016/j.ajpath.2013.09.027)Supported, in part, by the Susan G. Komen for the Cure grants
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nanovesicles released from normal and diseased cells into
interstitial spaces and, in some cases, into bodily ﬂuids.
Exosomes also are released by cultured cells into media.
Exosomes are deﬁned and separated from other vesicles
based on their source, method of isolation, sizes, and surface
markers. Exosomes and other vesicles frequently are unrec-
ognized as to their importance to physiological and patho-
logical processes because they are essentially invisible; their
small sizes keep them suspended in ﬂuids so that their effects
may not be identiﬁed in that their contents and functions
would seem to be consistent with those of soluble molecules.
Exosomes and related microvesicles were once thought to bestigative Pathology.
.
Exosomes and Cancerartifacts and/or cellular trash, but now exosomes are accepted
as a component of a newly identiﬁed intercellular communi-
cation system that can modulate the functions of target cells.
The involvement of exosomes and related microvesicles in
providing autocrine (ie, local signals between the same cell
type, such as cancer cells), paracrine (ie, local signals between
different cell types, such as between epithelial cancer cells and
stromal cells), and endocrine (ie, distant signals between any
types of cells usually carried in bodily ﬂuids, such as blood)
signals has led to the frequent use of the term, signalosomes,
being applied to these structures.
Exosomes and Related Microvesicles in Cancer
A speciﬁc subtype of exosome/vesicle/particle is released by
tumor cells (tumor-derived exosomes or TD-exosomes). TD-
exosomes/microvesicles may be released into the interstitial
space or even directly into lymphatics or into pseudocapillaries
formed by tumors. Also, the neovascularity of malignant tu-
mors is thought to be especially leaky and its permeability may
be inﬂuenced by exosomes, cytokines, and other local mole-
cules, such as vascular endothelial growth factor (VEGF).
The presence of TD-exosomes in patients with malignant
tumors leads to several important issues and concepts.1e23
1. Exosomes/microvesicles in the blood of patients with
tumors are composed of both exosomes/vesicles from
normal cells, diseased cells (comorbid conditions), and
TD-exosomes/microvesicles (Table 1). TD-exosomes are
characteristic of tumor cells and have different molecular
characteristics than microvesicles from other sources.
2. Tumor cells may release more microvesicles than other
cells, and TD-exosomes may have easier access to the
vascular system and, thus, may be selectively increased in
blood compared with microvesicles from other sources.
3. Smaller microvesicles with speciﬁc molecular surface
characteristics may selectively reach the blood and
larger microvesicles may remain in the interstitial space
and selectively provide autocrine and paracrine signals
to stromal, inﬂammatory, and endothelial cells.
4. Once speciﬁc cellular populations within the tumor are
affected by TD/exosomes/microvesicles, various modula-
tory loops may be established that facilitate the growth,
progression, and cellular dissemination of the tumor.Table 1 Source of Exosomes in a Patient with a Speciﬁc Malignant Pr
Independent of the tumor
Exosomes from normal cells
Exosomes from cells whose release is caused by nonneoplastic comor
Dependent on the presence of cancer
TD-exosomes from malignant cells
Exosomes from uninvolved cells (eg, adjacent uninvolved tissue that
Exosomes from normal cells induced by exosomes or other molecules fro
from tumor and associated stromal cells
Exosomes from immune cells affected by the cancer
Exosomes from the cells of a comorbid condition caused by the tumor
The American Journal of Pathology - ajp.amjpathol.org5. Via autocrine interactions, TD-exosomes may stimulate
malignant cells to grow, move, and invade the vascular-
lymphatic system and disseminate via chemotaxis to
nodal and other metastatic sites. Exosomes may establish
favorable environments at potential metastatic sites and
mayaid the survival of neoplastic cells at sites ofmetastases.
6. As part of establishing speciﬁc microenvironments and
interacting with various cellular compartments, chemo-
taxis is likely to be an important, although poorly
described, signaling pathway of exosomes.
7. Some tumors frequently induce thrombosis and, hence,
may cause an increase in microvesicles/microparticles
that are released from platelets. These microvesicles
have to be experimentally separated from microvesicles
derived from actual malignant cells or other types of cells.
8. TD-exosomes can interact with the normal cells of the
immune system to reduce immune surveillance by in-
creasing cells that inhibit immunity, decreasing antigen-
presenting cells (APCs), and inhibiting T and natural
killer (NK) cells.
9. Exosomes function in removal of waste products, drugs,
and/or less necessary molecules from cells and, hence,
exosomes may facilitate chemoresistance.
10. Exosomes/microvesicles have been reported to transfer
oncogenic features among malignant cells and tran-
siently to nonneoplastic cells, suggesting the probability
of lateral transfer of phenotypic features among cells.
11. Immunoseparations suggest that distinct populations of
exosomes may have different molecular characteristics
and may arise from different intracellular areas of polar-
ized cells.
12. Exosomes may be useful clinically and in translational
research by improving the analysis of biomarkers and
the delivery of therapeutic and preventive drugs, vac-
cines, and gene therapy; in addition, they may be useful
as targets to improve immunity.Characteristics of Exosomes
Signaling by exosomes and microvesicles is likely to be
affected by their morphological and molecular features. In
gaining entrance to the lymphatic-vascular system, smaller
nanoparticles are likely to have an advantage because theocess
bid conditions that are independent of the tumor
appears normal) induced by TD-exosomes
m the cancer (eg, soluble factors); this includes exosomes released
(eg, disseminated intravascular coagulation caused by the cancer)
29
Zhang and Grizzlemicrovesicles must pass through spaces between endothelial
cells via mechanisms that are not adequately deﬁned.
Similarly, the molecular characteristics of the external sur-
faces of exosomes may affect this passage and some exo-
somes are absorbed by endothelial cells and inﬂuence
secondary exosomes released from endothelial cells.
Subgroup of Microvesicles
Exosomes typically can be collected from blood via a series
of steps of centrifugation to remove larger cellular debris
and sometimes by ﬁltration through a 100- to 220-nm ﬁlter
to exclude larger microvesicles, including apoptotic blebs.
Subsequently, exosomes are pelleted by ultracentrifugation
at approximately 100,000  g for 60 minutes, washed, and
suspended by ultracentrifugation in a sucrose gradient. After
these steps, exosomes isolated from blood typically are
described via electron microscopy as spherical to cup sha-
ped, bilayered, membrane-bound nanovesicles ranging from
30 to 100 nm in greatest dimension. They are also described
by using Western blot analysis of the exosomal preparations
as demonstrating the presence of multiple molecular fea-
tures, including speciﬁc tetraspanins.1e12
When the usual steps are not taken during isolation
of exosomes, the nanoparticles presented in preparations
frequently are described as microvesicles, exosome-like par-
ticles, microparticles, or sometimes oncosomes if the micro-
vesicles transmit oncogenic properties to the target cells. There
is confusion because results based on microvesicles are
sometimes reported as from exosomes and vice versa. Both the
sources of microvesicles and their isolation affect their char-
acteristics: a 220-nm ﬁlter limits the sizes of microvesicles,
and sucrose gradient separations affect sizes via their density
and may remove molecules absorbed on exosomes.
If speciﬁc microvesicles are involved in intercellular
communication, is it important to classify microvesicles
based on their sizes and shapes? The effects of size-shape
characteristics have not been described adequately, but size,
shape, and surface characteristics may affect how exosomes
gain access to bodily ﬂuids and deliver signals to speciﬁc
cells with which they interact.12
Molecules phenotypically expressed on the external sur-
face of microvesicles separate nanovesicles originating from
multivesicular bodies (MVBs) from those arising from
budding from cellular membranes and, hence, deﬁne
different subgroups of microvesicles that may have different
morphological and molecular characteristics, different
sources, and, perhaps, different functions. Those markers
identiﬁed by using Western blot analysis may not be present
on all microvesicles and may not be associated with the
microvesicles producing speciﬁc functional characteristics.
Thus, the sizes, shapes, and surface molecules of micro-
vesicles may affect their concentration in blood.12 Micro-
vesicles isolated from ﬂuids other than blood may have
different morphological features; microvesicles isolated
from semen are described as being up to 500 mm and30containing intravesicular structures, from spent culture
media as biphasic in size (200 to 400 and 600 to 1000 nm),
and from saliva as doughnuts with a height/width ratio of
0.04.23e25 Exosomes isolated from ascites are described as
being similar to exosomes isolated from matching blood.26
The release of exosomes from normal and diseased (ie,
nonneoplastic) cells is affected by multiple factors, including
calcium, calcium ionophores, phosphatidylinositol 3-kinase,
heat, ischemia, cellular stresses, pH, phorbol esters, and loss
of cellular attachment.13,27e33 Hypoxia increases speciﬁc
exosomes that, in turn, may stimulate angiogenesis.13 As
would be expected, factors that affect the formation ofMVBs,
fromwhich exosomes speciﬁcally arise, affect the secretion of
exosomes; thus, exosomes are decreased by inhibitors of
phosphatidylinositol 3-kinase (wortmannin).
Multiple molecular factors control exosomes, including
the small GTPases (Rab) and p53 via TSAP6.34e36 The
complex of syndecan 1esyntenin and Alix affects the
intraluminal budding of exosomal membranes and, together
with an endosomal sorting complex responsible for trans-
port (ESCRT-III), these molecules cleave the membrane
buds. This complex may also be involved in growth factor
transport37,38 and may be related to control in exosomes of
selective protein sorting by ceramide.39 In addition, hepar-
anase, which may aid in the formation of the syndecan-1e
syntenineAlix complex, also stimulates the secretion of
classic exosomes.40 Although these molecular features
affect the secretion of exosomes, our knowledge of the
overall process is rudimentary. This same pathway may also
be used by speciﬁc viruses in their release from cells.33,36
Kinetics of Exosomes
The kinetics of release of exosomes is relatively rapid. After
loading of MCF-7 cells with doxorubicin, exosomes con-
taining doxorubicin showed presence at cellular membranes
within 3 hours.23 Similarly, after stimulation ofmast cells with
alloantigens, exosomes were released within 30 minutes.41
The internalization of exosomes by target cells is a rapid,
active process; one-third of dendritic cells (DCs) imported
exosomes at 37C within 2 hours. Internalization requires
metabolic energy and is decreased by EDTA, cytochalasin D,
and incubation of the target cells at 4C.31,41,42
Molecular Characteristics of Exosomes
Exosomes are deﬁned by speciﬁc molecular features, in-
cluding the phenotypic expression of speciﬁc surface mol-
ecules. The commonly used molecular markers of exosomes
are the surface tetraspanins, CD9, CD63, CD81, CD82,
CD151, and other molecules, including intercellular adhe-
sion molecule-1, avb3 (CD51 and CD61), integrin, Alix,
externalized phosphatidylserine, milk fat globule-E8/
lactoferrin, CD80, CD86, CD96, Rab-5b, and major histo-
compatibility complex (MHC) class I and MHC class II
complexes.7e9,31,32,41e46 Tetraspanins may form a netajp.amjpathol.org - The American Journal of Pathology
Exosomes and Cancerincorporating different tetraspanins and neighboring mole-
cules, and this net may be incorporated into MVBs and into
exosomes.47 Exosomes/microvesicles may vary with their
origin; the transferrin receptor is in exosomes from re-
ticulocytes and CD11a and CD54 in exosomes from he-
matopoietic cells. Exosomes from tumors may express
molecular features of the tumor type (eg, melanin A from
melanomas5,10e12,17e19,31,33,46,47).
Recent studies using colorectal cells have suggested that
when cells are polarized in three-dimensional cultures, two
subtypes of exosomes are secreted from different intracel-
lular locations. Speciﬁcally, approaches were used via which
larger microvesicles are excluded from preparations (ie,
ﬁltration through a 100-nm ﬁlter and concentration of the
specimen through a 5-kDa molecular weight limit mem-
brane). Exosomes were then separated from this preparation
by immunoafﬁnity based on a colonic epithelial cell type-
especiﬁc molecule, A33, followed by immunoafﬁnity sep-
aration based on Ep-CAM. The two types of exosomes that
were identiﬁed had slightly >50% of proteins in common;
however, there were approximately 20% different proteins in
the A33 cell-speciﬁc fraction and approximately 25%
different proteins in the Ep-CAM fraction. The Ep-CAM
fraction seemed to be primarily enriched in apical proteins
(eg, CD44 and tetraspanins), whereas the A33 fraction was
enriched in basolateral proteins, including clathrin and MHC
class I molecules. This observation, if independently
conﬁrmed in other cell types, will greatly expand our un-
derstanding of exosomes. Similarly, it is likely that there are
other subtypes of exosomes (eg, an exosome population
involved speciﬁcally in cellular waste management).
In that exosomes act in intercellular communication and
in exporting waste and less-needed products from cells,48,49
exosomes containing waste products are likely to have
surface molecules that instruct phagocytes to remove
them.48 For example, the phenotypic surface expression of
galectin-5 has been proposed as being important in the
removal of reticulocyte exosomes by macrophages.50 Other
signals may be analogous to those by which apoptotic cells
are phagocytosed.
The release of exosomes from normal and diseased cells
provides signals to other cells via their contents, which
include a wide range of functional molecules (eg, hundreds of
different proteins, mRNAs, miRNAs, and lipids).16,25,51e55
When mRNA contained in murine exosomes from mast
cells reacted with human mast cells, murine proteins were
produced in the human cells.52
Although miRNAs are a relatively new area of investiga-
tion, their impact on human diseases has been demonstrated
to be important.56,57 Thus, the observations that exosomes
frommultiple types of tumors contain miRNAs is noteworthy
but controversial, in that some reports indicate that most
circulating miRNAs are outside exosomes. Of interest, the
controversy is not whether exosomes contain miRNAs, but
rather the proportion of circulating miRNAs that are within
exosomes.58,59 It would likely be advantageous for allThe American Journal of Pathology - ajp.amjpathol.orgcirculating RNAs to be within exosomes. Exosomes are a
vehicle that can protect RNAs, but potentially can deliver
RNAs to speciﬁc target cells in which miRNAs may modu-
late mRNAs.56 Thus, the exosome is likely to be both a
typical chaperone for some miRNAs and their other molec-
ular contents, as well as a speciﬁc delivery pathway. As
previously indicated, exosomes are invisible unless they are
speciﬁcally looked for. To support the concept of invisibility,
a study challenging the reports indicating that most circu-
lating miRNAs are outside exosomes reported that most
circulating miRNAs from serum and saliva are contained
within exosomes.60 These studies have used serum and
plasma from normal patients; this issue may be more
important in exosomes released from tumors rather than
exosomes released from nonneoplastic cells. Tumor cells
have a high rate of cellular death and when the cells of tumors
die, their surviving contents, including RNAs, miRNAs, and
argonaute 2 complexes, could be dumped into the interstitial
space and picked up by the lymphatic-vascular system. Thus,
depending on the rate of death of the malignant cells of
speciﬁc tumors, it would not be surprising to ﬁnd miRNAs
both inside and outside exosomes, especially if complexed
with argonaute 2. Similarly, as discussed, the method of
isolation of exosomes may strongly affect the RNAs in
tumor-derived exosomes. Speciﬁcally, a proportion of exo-
somes may be destroyed on isolation, releasing their contents
into solution.58 The resolution of the question of whether
circulation miRNAs are primarily within or outside exo-
somes will obviously require much more study. The issue
may well relate to function in that miRNAs contained in
exosomes may be more biologically active with respect to
speciﬁc uptake by targeted cells.
Exosomes separated from saliva can affect proteins in
oral keratinocytes of humans25; thus, exosomes act as an
endocrine system and provide autocrine, paracrine, and
other signals to target cells. For example, microvesicles can
be exchanged among touching cells using tunneling nano-
tube networks.55,61 Although molecules in exosomes can
provide molecular signals to modulate target cells, how
target cells accept or reject the hundreds of different mole-
cules contained in microvesicles that could provide different
signals is not understood. More is known about the mo-
lecular signals that are accepted by target cells than those
that are ignored.
How exosomes from different cells target speciﬁc cells is
yet to be clariﬁed; however, there must be selective in-
teractions of exosomes with target cells, probably via in-
teractions with molecules on the external surface of
exosomes with interacting surface molecules on target cells.
Exosomes bind to the breast carcinoma cell line, BT-549,
via annexins A2 and A6 and the molecules of lipid rafts.32,62
The active uptake of exosomes by DCs can be only partially
blocked by monoclonal antibodies to surface molecules,
including CD9, CD11a, CD54, CD81, and avb3 integrin.
Each monoclonal antibody blocked internalization of exo-
somes by only approximately 30% of control values, but31
Zhang and Grizzlemonoclonal antibody to milk fat globule-E8/lactoferrin, a
surface molecule that potentiates uptake of apoptotic cells
by macrophages, stimulated the uptake of exosomes by
approximately 30%.42 How combinations of surface signals
potentiate uptake of exosomes remains to be clariﬁed. Of
interest, tetraspanins are involved in the fusion of HIV-1
with T cells and facilitate uptake of HIV-1 by DCs and
macrophages; thus, understanding the cellular uptake of
exosomes might be increased by a better characterization of
how cells are infected with viral particles and apoptotic cells
are phagocytosed by macrophages.47,63
How do cells decide which molecules to package into
exosomes? Waste or less-needed molecules could be pack-
aged into one type of vesicle, but signal molecules into
different microvesicles. Alternatively, if both types of
molecules are packaged into the same microvesicles, are the
waste molecules destined for degradation via molecular
modiﬁcation (eg, ubiquitinated) so that they are ignored by
the target cells? The JAB1/CSN5, a component of COP9,
seems to play a role in the sorting of proteins that are
ubiquitinated into exosomes, and this might be a step in
processing of waste molecules.64,65 Other waste molecules
may be sorted via the ESCRT-0, ESCRT-I, and ESCRT-II
pathways. The tetraspanins, especially CD81, complex
with some viral particles (eg, hepatitis C virus) to promote
their incorporation into exosomes63; however, viral particles
are much more complex than single molecules. Also, cer-
amide and heparanase seem to play a role in transferring
potential signal molecules into exosomes.39,40
Functions of Exosomes in Normal Physiological
Characteristics
Exosomes have been isolated from most normal biological
ﬂuids, including bronchoalveolar ﬂuid, cerebrospinal ﬂuid,
blood, urine, saliva, breast milk, amniotic ﬂuids, semen, and
synovial ﬂuid, and diseased ﬂuids, including ascites and
pleural effusions.24e26,51,66e69 Thus, exosomes are likely to
play important roles in normal physiological features and in
diseases. Most roles in normal physiology have not been
well characterized, except regarding the functions of exo-
somes in the immune system.
The Actions of Exosomes in the Normal Immune
System
Exosomes play important roles in the intercellular commu-
nication among normal immune cells, but communication
may typically be dysregulated in disease processes. Most
immune cells have been reported to secrete exosomes.
During their normal functions, mast cells, DCs, immature
APCs, macrophages, T and B lymphocytes, and NK cells
use exosomes to communicate.10e12
An excellent example of how exosomes affect the im-
mune system is their involvement in maternal-fetal toler-
ance.70e76 To protect the fetus, the placenta releases32exosomes, some of which phenotypically express Fas
ligand, an immunosuppressive and an anti-inﬂammatory
molecule.77e79 In addition, syncytiotrophoblasts secrete
exosomes that express ULBP 1 to 5, which are ligands to
the NKG2D receptor expressed on gdT, NK, and CD8þ T
cells. During pregnancy, an interaction of the NKG2D re-
ceptor with its ligands decreases the functions of immune
cells.72 Also, the chromosome 19 miRNA cluster, which
suppresses immunity and facilitates the growth of some
tumors, is present in placental exosomes.75,76 Thus, exo-
somes are involved in the decreased immunity that is
necessary for successful pregnancies.
Exosomes are an important feature in the processing of
antigens by APCs. The DCs can use exosomes in the pre-
sentation of processed antigens to NK cells and T lym-
phocytes. In this process, stimulating antigens or antigen
peptides are combined in MHC class II complexes present
on the surfaces of some exosomes and these MHC class II
antigen complexes then stimulate immune cells. The pre-
sentation of antigens/peptides by exosomes is much more
efﬁcient than if exosomes are not involved.80e83 At least
two different subpopulations of DCs are required for
optimal stimulation of T cells by exosomes. DCs carrying
an MHC class II antigen complex secrete exosomes that
carry the complex. These exosomes can be absorbed by
CD8a, CD80þ, and CD86þ DCs that can then process the
exosomes so that an exosomeeHLA class II antigenepep-
tide complex can be presented by DCs to immune cells,
such as CD4þ T cells. The activation of CD4þ T cells can
be ampliﬁed via transferring the HLA class II anti-
genepeptide complex to multiple DCs independent of their
expression of HLA class II complexes.80,81
CD8aþ DCs control peripheral immune tolerance via
modulation of the responses of CD4þ T cells to alloanti-
gens.42 Processing of exosomes by mature DCs is required
for stimulation of MHC class I restricted CD8þ T-cell re-
sponses. Adjuvant molecules, such as ligands for toll-like
receptors 3 and 9, aid in this stimulation.83 In addition,
mature B cells may be required for optimally stimulating T
cells by exosomes released by DCs.84
Other effects of exosomes on immune cells have been
reported; speciﬁcally, mast cells secrete exosomes that
activate B and T lymphocytes and DCs. Exosomes released
in vivo from murine mast cells facilitated the maturation of
DCs and increased the ability of DCs to present antigens to
T lymphocytes. The heat shock proteins, HSP60 and
HSP70, from exosomes have been reported to be important
for the presentation of antigens by DCs.41 Exosome-like
particles isolated from the spleen can modify CD4þ,
CD25 T cells and convert them into CD4þ, CD25þ,
Foxp3þ T-regulatory cells (Tregs). Tregs act to inhibit
autoreactive T cells and, thus, suppress dysregulated im-
mune responses and minimize autoimmunity.85 Exosomes
also are sometimes involved in dysregulation of normal
immunity and affect autoimmunity.86 Depending on the
source cells and their molecular content, exosomes mayajp.amjpathol.org - The American Journal of Pathology
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system, suggesting an involvement of exosomes in auto-
immunity. Exosomes from synovial ﬁbroblasts collected
from patients with rheumatoid arthritis, but not osteoar-
thritis, contain a membrane form of tumor necrosis factor
(TNF)-a, which potentiates the signaling of NF-kB and
suppresses apoptosis of activated T cells. This may increase
the severity of rheumatoid arthritis.87 Alternatively, exo-
somes from genetically modiﬁed immunosuppressive im-
mune DCs [eg, bone marrowederived DCs (BMDCs)] can
reduce autoimmunity. BMDC(s) expressing IL-10 or ex-
posed to IL-10 release exosomes that inhibit both the
inﬂammation and arthritis caused by injections of collagen
into mice.88 Similarly, when BMDCs are modiﬁed to ex-
press transforming growth factor (TGF)-b1, the develop-
ment of inﬂammatory bowel disease in mice, secondary to
dextran sodium sulfate, is inhibited by exosomes from the
TGF-b1 genetically modiﬁed BMDCs.89
Normal Functions of Exosomes in the Export of Waste
Products, Less-Needed Molecules, and Harmful
Molecules
Cells use exosomes to export waste products, molecules no
longer as useful as cells differentiate, and molecules, such as
drugs, that may be harmful to cells. This pathway can
eliminate proteins without signal sequences and permit their
secretion. Exosomes are especially important during cellular
differentiation when large amounts of molecules must be
removed from differentiating cells to optimize their more
differentiated functions (eg, metabolic active hematopoietic
precursor cells that differentiate to anucleate relatively
inactive red blood cells containing primarily hemoglobin).50Exosomes and Neoplasia
Exosomes are secreted by most types of cells, including
those of neoplastic lesions. The microvesicles released from
probably all malignant cells are designated as tumor derived
(TD). TD-microvesicles have been studied primarily in
bodily ﬂuids (eg, blood) and media from cultured cells.
Exosomes/microvesicles in bodily ﬂuids are complex, as
is the molecular composition of bodily ﬂuids, because both
microvesicles and free molecules in bodily ﬂuids are from
normal and diseased cells. Similarly, as noted previously,
exosomes and microvesicles, as well as their contents and
effects, are invisible unless analyzed as a separate compo-
nent of ﬂuids. Thus, measurements of the molecular con-
tents of TD-exosomes potentially should be just as sensitive
and speciﬁc for clinical uses and in translational research as
measurements of the same molecules external to exosomes.
TD-exosomes/microvesicles mirror the molecular features
of the source neoplastic lesions. For example, TD-exosomes
in blood from patients with glioblastoma multiforme and
high-grade gliomas contain neural markers (eg, LI-NCAM/The American Journal of Pathology - ajp.amjpathol.orgCD171)88e91 and exosomes from melanomas that express
molecules involved in melanin synthesis and other mela-
noma markers (eg, Melan A/Mart 1).5,46,92
Exosomes Decrease the Immune Surveillance of Tumors
Via its normal functions, the immune system should mini-
mize the development and progression of cancers; however,
malignant lesions have been found to inhibit immune sur-
veillance, resulting in their more rapid growth, progression,
and dissemination.10e12,93e99 Speciﬁcally, tumors have
increased growth in vivo after injection of exosomes isolated
from matching neoplastic lesions.93 Exosomes ultimately
were found to inhibit immunity by several mechanisms,
including increases in suppressive immune cells, decreases in
the proliferation and cytotoxicity of NK and T cells, and
decreases in the number and functions of APCs.10e12 Thus,
the decrease in immunity caused by neoplastic lesions is
primarily mediated by exosomes released from tumors.93e101
The intercellular signals provided by TD-exosomes to the
immune system probably vary with different types of can-
cers. Oral and ovarian epithelial neoplastic lesions secrete
exosomes/microvesicles that contain Fas ligand, Trail, or
related molecules (eg, TNFa), which can cause apoptosis of
activated T lymphocytes via suppression of CD3z and Jak-
3.77e79,95 However, some TD-exosomes that increase the
growth of their source tumors do not contain Trail or Fas
ligand, but interact with NK cells to decrease the secretion
of perforin, inhibit Jak-3, and decrease cyclin D3.93 Thus,
TD-exosomes are likely to decrease immunity via several
mechanisms. For example, exosomes containing TGF-b1
may decrease the expression of the NKG2D receptor via, in
part, miRNA-1245, and reduce the activation of NK and
CD8þ T cells.96,97
TD-exosomes also decrease immunity by decreasing the
numbers and/or activity of APCs, including DCs. Signals
from TD-exosomes increase the phosphorylation of Stat 3
and the expression of IL-6 in DCs, decreasing the activity of
DCs and the numbers of APCs via inhibiting the dif-
ferentiation of CD14þ monocytes into mature APCs.98 In
addition, CD14þ cells shift to immunosuppressive CD14þ
HLA-DR-/low cells, which release TGF-b to inhibit T
cells.99,100
TD-exosomes increase myeloid-derived suppressor cells
(MDSCs). In humans, the numbers of MDSCs in neoplastic
lesions are correlated with the neoplastic progression and
decreased patient survival, probably via inhibiting NK cells
and CD4þ and CD8þ lymphocytes by MDSCs.101e103
MDSCs (CD11bþ, Gr-1þ) are increased in neoplastic le-
sions, spleens, and blood of mice with transplanted synge-
neic tumors, and they are decreased in the blood and spleens
of mice by removal of transplanted tumors.102 Exosomes
increase MDSCs via TGF-b, which increases prostaglandin
E2.104 TD-exosomes also increase MDSCs via MyD88, but
effects of TLR pathways on MDSCs should be considered
carefully because of potential phenotypic changes in cells,33
Figure 1 A scheme summarizing some of the
complex effects of TD-exosomes on the immune
system and how TD-exosomes suppress immune
surveillance by decreasing the proliferation and
activation of T and NK cells, decreasing mature
antigen presenting cells (APC) and increasing cells
such as myeloid-derived suppressor cells and Tregs,
which suppress immunity. HSP72, heat shock pro-
tein 72; JAK3, Janus kinase 3; MyD88, myeloid
differentiation primary response 88; PGE2, prosta-
glandin E2; pStat3, phosphorylated signal trans-
ducer and activator of transcription 3; TGF-b,
transforming growth factor b; TNF-a, tumor ne-
crosis factor a.
Zhang and Grizzleinduced by long-term cultures.9e11,105,106 In addition to the
actions of exosomes, release of cellular soluble mediators,
such as granulocyte-macrophage colony-stimulating factor,
from neoplastic cells also may increase MDSCs.
Another immune-suppressive cellular population that is
increased by exosomes is Tregs. TD-exosomes can induce
the differentiation of CD4þ, CD25þ T cells to CD4þ,
CD25þ, Foxp3þ Tregs via the phosphorylation of both Stat
3 and SMAD2/3.98,107
Figure 1 summarizes how neoplastic lesions can partially
avoid immune surveillance by secreting TD-exosomes,which
inhibit the activity of T and NK cells, by decreasing APCs,
and by increasing cells that suppress immune surveillance,
such as Tregs, MDSCs, and CD14þ-HLA-DR-/low cells.34Nonimmune Effects of Exosomes on Primary Malignant
Lesions
The development, progression, and dissemination of ma-
lignant tumors depends on a balance of cellular proliferation
and cellular death (eg, apoptosis and autophagy). TD-
microvesicles can provide autocrine, paracrine, endocrine,
and other signals that can generate fertile environments to
support malignant lesions and, hence, stimulate their
growth, progression, and metastasis (Figure 2).13e22
An important pathway by which TD-exosomes modulate
the local environment of cancers is one that stimulates
angiogenesis and, hence, increases the supply of oxygen
and nutrients to the growing tumor.1,13,16e18,22,90,91,108,109Figure 2 A scheme indicating the potential
local effects of TD-exosomes on cancer cells. The
divisions of boxes represent potential different
exosomal compartments that interact with the
microenvironment of the tumor. Paracrine net-
works are represented between ﬁbroblasts, myoﬁ-
broblasts, and malignant cells.
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Exosomes and CancerSpeciﬁcally, exosomes secreted by melanomas are reported
to facilitate the formation of spheroids by endothelial cells
and budding of these spheroids. Also, cytokines, including
TGF-b and VEGF, that stimulate angiogenesis are contained
in exosomes secreted from malignant cells in hypoxic and
similar environments.13,16 Similarly, the blood from patients
with glioblastomas and from the media of their short-term
cultures has been reported to contain microvesicles with
the pro-angiogenic proteins, angiogenin, VEGF, IL-6, and
IL-8. The microvesicles were enriched in angiogenic pro-
teins compared with the source glioblastomas, and these
microvesicles stimulated increases in the length of endo-
thelial tubes and in angiogenic proteins.90,91,108,109 Also, on
exposure to hypoxia, A431 cells secrete exosomes that
contain molecules that stimulate angiogenesis and facilitate
metastasis.13
TD-exosomes may modulate the local growth of neo-
plastic lesions via autocrine signals provided by exosomes.
Autocrine effects of exosomes have been reported to vary
with cellular characteristics and cell type. For example,
exosomes from pancreatic cancers increased apoptosis via
the Notch pathway if the cell lines were well differentiated,
but not if the cell lines were poorly differentiated; thus,
exosomal autocrine signals might inhibit the growth via
stimulating apoptosis of some pancreatic neoplastic lesions,
but not others.110,111 Alternatively, autocrine signals medi-
ated by exosomes from the BT-474 breast cancer cell line,
gastric cancer cell lines, and glioma cells increased cellular
proliferation.2,90,112 The mechanism of the increased pro-
liferation of the gastric cancer cell lines was thought to be
via increased phosphorylation of Akt and extracellular sig-
naleregulated kinase, which, with other downstream mol-
ecules, are associated with cellular proliferation. Growth of
the glioblastoma cell line, U87, was increased via exosomes
derived from primary glioblastomas; although this growth
was assumed to be secondary to increased proliferation,
decreased apoptosis was not excluded.90 Survivin and heat
shock proteins, HSP70 and HSP90, may be increased in
exosomes in association with cellular stresses. These pro-
teins may inhibit apoptosis and increase cellular prolifera-
tion and invasion so they provide a strong stimulus to the
microenvironment that can facilitate the growth and
dissemination of primary tumors.31,113
In addition to exosomes, microvesicles of other types
may be secreted by neoplastic cells into the local microen-
vironment of primary tumors. Speciﬁcally, PC-3, a prostatic
cancer cell line, released microvesicles distinct from exo-
somes, which stimulated ﬁbroblasts, and the ﬁbroblasts
responded by an increased release of microvesicles that
stimulated PC-3 cells to migrate and invade. This paracrine
loop associated with the CX3CL1 and CX3CR1 was not
observed in LNCaP cells, which are not as aggressive as
PC-3 cells.14 The variable responses of PC-3 and LNCaP
cells to microvesicles from ﬁbroblasts might be due to
different molecular features within or on exosomal surfaces,
such as the binding complex, type III receptor beta glycan,The American Journal of Pathology - ajp.amjpathol.organd its associated ligand, TGF-b, which are expressed
strongly in PC-3 cells, but not on or in LNCaP cells.15
TD-exosomes can induce changes in ﬁbroblasts indica-
tive of a transition to myoﬁbroblasts. Fibroblasts/myoﬁ-
broblasts then may modulate the microenvironment (eg,
degradation of the extracellular matrix and increased pro-
duction of pericellular hyaluronic acid) to facilitate the in-
vasion of neoplastic cells. Also, ﬁbroblasts/myoﬁbroblasts
may aid in the induction of epithelial-mesenchymal transi-
tions of malignant cells.15 Thus, TD-exosomes typically
increase the growth and progression of primary neoplastic
lesions via the induction of phenotypic changes that facili-
tate more aggressive cellular characteristics.
Exosomes can provide an efﬁcient and speciﬁc transfer
of molecular signals between cells. If these signals in-
duce oncogenic changes in the cellular phenotype, TD-
microvesicles are sometimes referred to as oncosomes. A
variant of the epidermal growth factor receptor (EGFR) vIII
has oncogenic features via unregulated stimulation of the
Akt/mitogen-activated protein kinase pathway that, for
example, increases VEGF. Microvesicles from xenografts of
glioblastomas have been reported to transfer EGFRvIII to
glioma cells lacking this phenotypic feature. Because the
EGFRvIII expression remained stable in malignant cells to
which EGFRvIII had been transferred, such transfer of
oncogenic features could be a mechanism via which onco-
genic features can horizontally spread among cells. In
response to continuing exposure to exosomes, endothelial
cells also transiently developed an EGFRvIII-expressing
phenotype, resulting in increased growth and, hence, prob-
ably increased angiogenesis. The phenotypic features of
endothelial cells associated with increased levels of
EGFRvIII were not stable and ended when the exposure to
the TD-exosomes containing EGFRvIII ceased.90,91,108,109
Induction of an oncogenic phenotype via larger TD-
microvesicles isolated from the MDA-MB-231 breast can-
cer cell line and the U87 glioma cell line also has been
reported. Microvesicles released from these cell lines con-
tained both tissue transglutaminase and ﬁbronectin, a tissue
transglutaminase substrate. These microvesicles caused
NIH/3T3 ﬁbroblast and benign breast epithelial cells,
MCF10A, to develop some aspects of malignant behavior,
such as anchorage-independent growth in agar and growth
in medium with low concentrations of serum. Maintenance
of these features of malignant behavior in nonmalignant
cells also required continuous exposure to TD-micro-
vesicles.114,115 Local effects of exosomes on primary
neoplastic lesions are demonstrated in Figure 2.
Exosomes Facilitate Metastases
How and where tumors metastasize are affected by multiple
molecular features, including functioning genes in primary
tumors that stimulate or inhibit metastases.116 TD-exosomes
from primary tumors promote the metastatic spread of tu-
mors by inducing features at potential metastatic sites that35
Figure 3 A model for the effects of TD-
exosomes on metastasis based on studies of me-
tastases of melanomas. HSP72, heat shock protein
72; JAK3, Janus kinase 3; MAPK, mitogen-activated
protein kinase; MyD88, myeloid differentiation
primary response 88; PGE2, prostaglandin E2;
pStat3, phosphorylated signal transducer and acti-
vator of transcription 3; UPA, urokinase plasmin-
ogen activator; TGF-b, transforming growth factor
b; TNF-a, tumor necrosis factor a.
Zhang and Grizzleattract neoplastic cells and build a matrix for their attach-
ment, aid neoplastic cells at the metastatic site to survive,
stimulate angiogenesis, and suppress immunity.19e22 Thus,
there is likely a role of exosomes in the release of their
chemotactic contents or the stimulation of nonneoplastic
cells to release chemotactic molecules in attraction of ma-
lignant cells to potential sites of metastasis.
TD-exosomes induce molecular features that cause ma-
lignant cells to leave the primary tumor and, via chemotaxis,
facilitate the migration of neoplastic cells to sentinel lymph
nodes, where exosomes establish a supportive environment
that promotes metastases. Speciﬁcally, exosomes from mel-
anomas stimulate the production of avb3 integrin, ephrin
receptor b4, and stabilin 1, which act to recruit melanoma
cells to the ipsilateral sentinel lymph node. Exosomes from
melanomas also induce the production of collagen 18, lam-
inin 5, mitogen-activated protein kinase (p38), and urokinase
plasminogen activator protease, which aid in the production
of the matrix necessary to support the growth of metastatic
cells. In addition, exosomes also increase nodal metastases
by inducing angiogenesis via inducing the expression of
VEGFb, TNFa, and hypoxia-inducible factor 1a19; simi-
larly, exosomes affect the programmed development of some
BMDCs via up-regulation of MET to produce a provascu-
logenic phenotype that facilitates angiogenesis and metas-
tasis.21,22 Figure 3 demonstrates some of the features that
facilitate metastases to ipsilateral lymph nodes.
TD-exosomes may interact with soluble factors from tu-
mors to facilitate metastases. For example, when the
conditioned media from cultures of cells of a syngeneic
pancreatic tumor model were separated into exosomal and
soluble components, exosomes were more effective than
the soluble factors in increasing metastases to lymph nodes
and/or lung; however, the combined soluble and exosomal36fractions were more effective in increasing metastases.20
The facilitation of metastases by exosomes was greatly
decreased when there was knockdown of CD44 splice
variants, especially CD44v6, on which production of matrix
depends. This matrix, which supports the attachment and
growth of metastatic cells, contained c-Met and urokinase-
type plasminogen activator receptor,20 which have been
reported to increase metastases.21,22
Much of the work on how exosomes affect metastases is
based on the responses of melanomas to TD-exosomes/
microvesicles from cell lines grown in vitro in standard two-
dimensional cultures. There needs to be increased character-
ization of the effects of exosomes in vivo in providingautocrine,
paracrine, and endocrine signals that modulate the growth,
progression, and metastases of tumors other than melanomas.
TD-Exosomes Increase the Resistance of Tumors to
Therapies
Exosomes normally function in the export of waste products
and less-needed molecules from cells and many harmful
products, such as exogenous molecules.4,23,49 In cancers,
exosomes also function to export chemotherapeutic drugs,
such as cisplatin and doxorubicin; thus, TD-exosomes are
used as a pathway of chemoresistance of speciﬁc malignant
cells to speciﬁc drugs. All drugs are not exported from cells.
For example, TD-exosomes do not export 5-ﬂuorouracil
efﬁciently. When factors associated with the shedding of
exosomes were combined into a vesicle-shedding index, the
vesicle shedding index of theNationalCancer Institute 60-cell
line panel was found to be positively correlated with 50%
growth inhibition for most of the 171 compounds of the Na-
tional Cancer Institute Standard Anticancer Agent Database.
Also, the actual shedding rate of microvesicles from six cellajp.amjpathol.org - The American Journal of Pathology
Exosomes and Cancerlines correlated positively with doxorubicin resistance;
however, there was no correlation of vesicle shedding with
chemoresistance to 5-ﬂuorouracil.23
The secretion of drugs in exosomes, such as doxorubicin,
may involve vacuolar protein sorting 4a,which is important in
the secretion of exosomes. Speciﬁcally, disruption of vacu-
olar protein sorting 4a in the erythroleukemic cell line, K562,
inhibited the efﬂux of doxorubicin.117 Thus, exosomes are
likely to be amajor factor in the chemoresistance ofmalignant
cells to a variety of, but not all, chemotherapeutic drugs.The Potential Clinical Impact of Exosomes
The molecular features of TD-exosomes mirror many of the
molecular features of the tumors from which they arise. TD-
exosomes have been reported to contain biomarkers char-
acteristic of tumors, including those of the bladder, brain,
colorectum, kidney, and melanomas, so the presence of
biomarkers characteristic of tumors in exosomes of bio-
logical ﬂuids may aid in clinical decisions and in trans-
lational research on biomarkers. Thus, TD-exosomes may
be important in clinical decisions, including risk assessment,
early detection, and diagnosis, in the prediction of therapeutic
efﬁcacy, and in determining prognosis. They may also be
important as surrogate end points in evaluating chemothera-
peutic, preventive, and novel therapies. Of special importance
in translational research is that exosomes are carried in blood
and are shed into biological ﬂuids, such as ascites and pleural
ﬂuids, all of which can be obtained easily for clinical use. As
discussed, themeasurements of biomarkers in exosomes from
bodily ﬂuids are likely to be just as sensitive and speciﬁc as
measurements of the same biomarkers in the matching bodily
ﬂuids. When speciﬁc biomarkers or biomarker panels (sig-
natures) are more concentrated in exosomes, their measure-
ments in the exosomal fraction may be more effective in
solving clinical problems than their measurements in match-
ing bodily ﬂuids.90,91,108,109 However, because exosomes and
microvesicles and their contents are essentially invisible, use
of the exosomes/microvesicles in translational research is in
its infancy.
A biomarker of ovarian epithelial tumors, Claudin 4, has
been found to be increased in exosomes separated from the
blood of patients with ovarian carcinoma,118 and trans-
membrane protease, serine 2-ETS related gene, d-catenin,
and prostate cancer antigen 3, which are potential biomarkers
for cancers of the prostate, have been measured in TD-
exosomes isolated from the urine samples of patients with
prostate cancer.119 Similarly, miRNAs may aid in the early
diagnosis of cancers of the lung via their measurement in TD-
exosomes.120 Biomarkers measured in exosomes also may be
useful in measuring responses to therapy.
Some TD-exosomes that contain increased concentrations
of speciﬁc tumor antigens could be used to stimulate DCs to
secrete exosomes that initiate cytotoxic T-lymphocytic re-
sponses.5,6 The generation of exosomes by DCs in vitroThe American Journal of Pathology - ajp.amjpathol.orgwould be an approach that could avoid the negative effects
(eg, reduction of immunity) of using TD-exosomes in vivo.
To date, the clinical results of using exosomes in cancer
therapy have been modest, but there have been few major
adverse effects.10e12
Because of the suppression of immune surveillance by
TD-exosomes, TD-exosomes could be targeted to reduce the
suppression of immunity in patients with cancers. Strategies
have been proposed to increase immune reactions to cancer
by reducing the transfer to TD-exosomes of molecules that
suppress the immune system. Alternatively, molecules that
may stimulate immune cells might be introduced into TD-
exosomes. Similarly, the function of TD-exosomes in
cellular export of drugs could be targeted to increase the
effectiveness of many drugs by reducing the release of TD-
exosomes via changing local pH or targeting the pathways
involving TD-exosomes, such as the VSP4a signaling
pathway.10e12,117,121 TD-exosomes also could be decreased
in blood using a hemopuriﬁer that selectively removes TD-
exosomes from blood by immobilized antibodies that bind
to the surface molecules of TD-exosomes.
Because TD-exosomes can be absorbed speciﬁcally by
neoplastic cells, they could deliver drugs, preventive agents,
small molecules (eg, miRNAs), and agents of gene therapy to
the cells of speciﬁc tumors.122e126 Curcumin is a natural
product with anti-tumor and anti-inﬂammatory features
whose bioavailability and therapeutic efﬁcacy is limited
because of poor solubility. Its clinical usefulness is improved
by the incorporation of curcumin into exosomes, which were
much more effective than liposomes containing curcumin in
preventing septic shock in a murine model.122e124 Both
drugs and miRNAs could be delivered speciﬁcally by exo-
somes to neoplastic cells.125,126
The clinical uses of microvesicles are being studied by
commercial and academic organizations as vehicles to
deliver chemotherapy, small molecules, agents of gene
therapy, and/or prevention to target cells more speciﬁcally
than systemic administration. Thus, multiple approaches to
the selective delivery of therapeutic and preventive agents
via biological microvesicles are in active development.Summary
Exosomes and related microvesicles compose a newly identi-
ﬁed method of local and distant intercellular communication.
Tumors have hijacked this mechanism of intercellular
communication to aid in their growth, progression, and
dissemination. TD-exosomes can act to produce a fertile envi-
ronment to support growth at primary sites of neoplastic lesions
and potential sites of metastases. TD-exosomes also may
facilitate tumor growth and dissemination by inhibiting im-
mune surveillance and by increasing chemoresistance via
removal of chemotherapeutic drugs. Thus,TD-exosomesmight
be potential targets for therapeutic interventions via their
modiﬁcation or removal. Exosomes and related microvesicles37
Zhang and Grizzlealso could serve as speciﬁc delivery vehicles to neoplastic le-
sions of drugs, small molecules, or agents of prevention and
gene therapy. In other clinical approaches, TD-exosomes could
serve as a subcompartment in which biomarkers could be
measured to aid in the early detection and diagnosis of diseases,
determining prognosis, prediction of therapeutic efﬁcacy, and
therapeutic responses. Such approaches would use the molec-
ular features of TD-exosomes that are different from exosomes
of either associated or diseased controls, or from normal
individuals.
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